Doron Greenbaum
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$9.6MFederal grants as PI8 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
8 awards · $9.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| 2018 | NIH | SBIR Phase I Calpain Therapeutics to Inhibit Myofibroblast Generation in Fibrosis | $202K | PHELIX THERAPEUTICS LLC |
| Dec 22, 2017 | NIH | SBIR Phase I Calpain Therapeutics to Inhibit Myofibroblast Generation in Fibrosis | $202K | PHELIX THERAPEUTICS LLC |
| Feb 21, 2017 | NIH | SBIR Phase II CATHEPSIN L INHIBITORS AS PAN-CORONAVIRUS THERAPEUTICS | $1.4M | PHELIX THERAPEUTICS LLC |
| Feb 29, 2016 | NIH | SBIR Phase II CATHEPSIN L INHIBITORS AS PAN-CORONAVIRUS THERAPEUTICS | $1.5M | PHELIX THERAPEUTICS LLC |
| Jul 1, 2015 | NIH | SBIR Phase I Cathepsin B Inhibitors as Therapeutics for Ebola Infection | $222K | PHELIX THERAPEUTICS LLC |
| Jun 15, 2015 | NIH | SBIR Phase I Cathepsin B Inhibitors as Therapeutics for Ebola Infection | $222K | PHELIX THERAPEUTICS LLC |
| Mar 1, 2015 | NIH | SBIR Phase II CATHEPSIN L INHIBITORS AS PAN CORONAVIRUS THERAPEUTICS | $4.4M | PHELIX THERAPEUTICS LLC |
| Feb 13, 2015 | NIH | SBIR Phase II CATHEPSIN L INHIBITORS AS PAN-CORONAVIRUS THERAPEUTICS | $1.5M | PHELIX THERAPEUTICS LLC |
Peer ranks
Federal funding#66
Awards as PI#190
Patents#273
Companies
- PHELIX THERAPEUTICS LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.